24 Facts About Hoffmann-La Roche


Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics.

FactSnippet No. 1,077,978

Hoffmann-La Roche is the fifth largest pharmaceutical company in the world by revenue, and the leading provider of cancer treatments globally.

FactSnippet No. 1,077,979

Hoffmann-La Roche is one of the few companies increasing their dividend every year, for 2020 as the 34th consecutive year.

FactSnippet No. 1,077,980

Hoffmann-La Roche is a full member of the European Federation of Pharmaceutical Industries and Associations .

FactSnippet No. 1,077,981

That year Hoffmann-La Roche then merged it with all of its laboratories, and incorporated the merged company as Roche Biomedical Laboratories, Inc in Burlington.

FactSnippet No. 1,077,982

Hoffmann-La Roche acquired Syntex in 1994 and Chugai Pharmaceuticals in 2002.

FactSnippet No. 1,077,983

Hoffmann-La Roche is the only drug company authorized to manufacture the drug, which was discovered by Gilead Sciences.

FactSnippet No. 1,077,984

On 20 October 2005 Hoffmann-La Roche decided to license other companies to manufacture Oseltamivir.

FactSnippet No. 1,077,985

Also in 2005 Hoffmann-La Roche acquired the Swiss company GlycArt Biotechnology in order to acquire technology to afucosylate antibodies; one of its products in development was obinutuzumab, which gained FDA approval in November 2013 for the treatment of chronic lymphocytic leukemia.

FactSnippet No. 1,077,986

On 12 March 2009 Hoffmann-La Roche agreed to fully acquire Genentech, in which it had held a majority stake since 1990, after eight months of negotiations.

FactSnippet No. 1,077,987

Hoffmann-La Roche began vacating the NJ site in 2012, and sold it off in 2016.

FactSnippet No. 1,077,988

In March 2011, Hoffmann-La Roche acquired PVT Probenverteiltechnik GmbH for up to €85 million.

FactSnippet No. 1,077,989

In July 2010, Hoffmann-La Roche acquired mtm laboratories AG for up to 190 million EUR.

FactSnippet No. 1,077,990

In July 2013, Hoffmann-La Roche Diagnostics acquired blood diagnostics company Constitution Medical Inc for $220 million.

FactSnippet No. 1,077,991

On 7 April 2014, Hoffmann-La Roche announced its intention to acquire IQuum for up to $450 million, as well as the rights to an experimental drug from Spanish company Oryzon Genomics for $21 million and up to $500 million in milestone payments.

FactSnippet No. 1,077,992

In February 2018, Hoffmann-La Roche announced it would acquire Flatiron Health, a business specialising in US cancer data analytics, for $1.

FactSnippet No. 1,077,993

In March 2021, Hoffmann-La Roche announced it would acquire GenMark Diagnostics for $1.

FactSnippet No. 1,077,994

Hoffmann-La Roche family is Switzerland's richest and one of the most secretive families.

FactSnippet No. 1,077,995

All business areas except Hoffmann-La Roche Applied Science focus on health care applications, targeting either physicians, hospitals and clinics, or consumers.

FactSnippet No. 1,077,996

Hoffmann-La Roche develops drugs used for cancer treatment, against virus diseases and for treatment of metabolic diseases.

FactSnippet No. 1,077,997

Hoffmann-La Roche was fined accordingly, but a bungle on the part of the EEC allowed the company to discover that it was Adams who had blown the whistle.

FactSnippet No. 1,077,998

Hoffmann-La Roche's wife, having learnt that he might face decades in jail, committed suicide.

FactSnippet No. 1,077,999

Hoffmann-La Roche paid $500 million in criminal fines to the United States.

FactSnippet No. 1,078,000

Hoffmann-La Roche is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.

FactSnippet No. 1,078,001